BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33438033)

  • 1. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
    Gill CM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Lasko MJ; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
    Lasko MJ; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
    Kidd JM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
    Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.
    Abdelraouf K; Almarzoky Abuhussain S; Nicolau DP
    J Antimicrob Chemother; 2020 Dec; 75(12):3601-3610. PubMed ID: 32862218
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 11. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
    Lasko MJ; Nicolau DP; Asempa TE
    J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems.
    Abdelraouf K; Reyes S; Nicolau DP
    J Antimicrob Chemother; 2021 Feb; 76(3):684-691. PubMed ID: 33179050
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Monogue ML; Tabor-Rennie J; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model.
    Gill CM; Asempa TE; Nicolau DP
    J Antimicrob Chemother; 2021 Jan; 76(1):184-188. PubMed ID: 33103202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
    Sader HS; Carvalhaes CG; Mendes RE; Castanheira M
    Int J Infect Dis; 2022 Mar; 116():306-312. PubMed ID: 35066163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
    Craig WA; Andes DR
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1577-82. PubMed ID: 23274659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
    Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.